Current achievements and future perspectives of metronomic chemotherapy.

Item

http://www.wikidata.org/entity/Q38788234

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Current achievements and future perspectives of metronomic chemotherapy.

@en

type

Item

label

Current achievements and future perspectives of metronomic chemotherapy.

@en

prefLabel

Current achievements and future perspectives of metronomic chemotherapy.

@en

P1476

Current achievements and future perspectives of metronomic chemotherapy.

@en

P2093

Adriana Romiti

http://www.w3.org/2001/XMLSchema#string

Michela Roberto

http://www.w3.org/2001/XMLSchema#string

Rosa Falcone

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer

Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial

The immune contexture in human tumours: impact on clinical outcome

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer

Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.

Bevacizumab and daily temozolomide for recurrent glioblastoma.

P2888

s10637-016-0408-x

P304

359-374

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-016-0408-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Marchetti

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047067068

http://www.w3.org/2001/XMLSchema#string

P698

27909934

http://www.w3.org/2001/XMLSchema#string